Trial Profile

A multicenter, phase 2 study to evaluate safety and efficacy of panitumumab re-challenge based on circulating tumor DNA analysis in patients with RAS/BRAF V600E wild-type unresectable metastatic colorectal cancer with prior treatment history of anti-EGFR antibody

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Oct 2024 Planned number of patients changed to 50.
26 May 2022 According to an Amgen media release, results from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2022.
02 Nov 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com